Table 1.
Mutations at CpG site | Control | Acrb | BPDEc | p53d | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
UMa | Ma | UM | M | UM | M | ||||||
G to T | 2 (40%) | 1 (6%) | 9 (36%) | 15 (54%) | 10 (48%) | 20 (71%) | 296 (49%) | ||||
G to A | 2 (40%) | 17 (94%) | 7 (28%) | 11 (39%) | 1 (4%) | 3 (11%) | 219 (36%) | ||||
Otherse | 1 (20%) | 0 (0%) | 9 (36%) | 2 (7%) | 10 (48%) | 5 (18%) | 96 (15%) |
UM: unmethylated supF; M: methylated supF.
Acr: 0.5 mM at 37°C for 24 h.
BPDE: 2μM at 37°C for 1 h.
CpG sites at codons 157, 158, 175, 245, 248, 273 and 282 of p53 in TS-related lung cancer.
Other types of mutations including G to C, insertion, deletion or tandem mutations.